To investigate the efficacy, safety, and compliance of a simplified strategy using vonoprazan plus clarithromycin for first-line treatment in patients with Helicobacter pylori infection, among those infected with strains without clarithromycin resistance gene mutations based on fecal clarithromycin resistance gene detection.
Aged 18-70 years;
Positive results for both ¹³C-urea breath test (¹³C-UBT) and fecal polymerase chain reaction (PCR), confirming Helicobacter pylori infection, with a clinical indication for H. pylori eradication as judged by the physician;
Treatment-naïve individuals with no prior history of H. pylori eradication therapy.
Pregnant or lactating women
Patients with a history of allergy to any drugs used in the eradication regimen
Patients with severe systemic diseases or malignant tumors
History of gastric resection surgery